

# Prognostic significance of aquaporins in human biliary tract carcinoma

SHINICHI SEKINE<sup>1</sup>, YUTAKA SHIMADA<sup>1</sup>, TAKUYA NAGATA<sup>1</sup>, MAKOTO MORIYAMA<sup>1</sup>,  
TETSUYA OMURA<sup>1</sup>, TOMOKO WATANABE<sup>1</sup>, RYOUTA HORI<sup>1</sup>, ISAKU YOSHIOKA<sup>1</sup>,  
TOMOYUKI OKUMURA<sup>1</sup>, SHIGEAKI SAWADA<sup>1</sup>, JUNYA FUKUOKA<sup>2</sup> and KAZUHIRO TSUKADA<sup>1</sup>

Departments of <sup>1</sup>Surgery and Science, <sup>2</sup>Surgical Pathology, University of Toyama, Toyama, Toyama 930-0194, Japan

Received December 28, 2011; Accepted February 15, 2012

DOI: 10.3892/or.2012.1747

**Abstract.** Aquaporins (AQPs) are important in controlling bile formation, however, the exact role of AQPs in human biliary tract carcinogenesis has not been clearly defined. In this study, we analyzed AQP-1, -4, -5 and -8 expression immunohistochemically using tissue microarrays (TMAs) in 81 samples. (45 gallbladder carcinomas and 36 bile duct carcinomas). The survival of patients with high AQP-5 expression was longer compared to that of patients with low AQP-5 expression ( $P=0.017$ ). Cox's proportional hazard model revealed that AQP-5 expression was an independent prognostic factor (RR, 0.38;  $P=0.025$ ). Chi-square analysis revealed that high AQP-5 expression correlated to small tumor size in biliary tract carcinoma patients ( $P=0.006$ ). With regard to the expression of other AQPs, depth of tumor invasion, histological type and serum carbohydrate antigen 19-9 (CA19-9) were associated with high AQP-1 expression ( $P=0.039$ , 0.011 and 0.032). However, AQP-4 and AQP-8 expression had no association with clinicopathological factors. Among the 10 patients who underwent gemcitabine (GEM) plus S-1 postoperative chemotherapy, the group of patients ( $n=5$ ) with high AQP-5 expression were associated with higher rates of both overall and disease-free survival (log-rank  $P=0.033$ , 0.002). In conclusion, the results of this study suggest that AQP-5 expression may be associated with prognosis and drug sensitivity in biliary tract carcinoma.

---

*Correspondence to:* Dr Shinichi Sekine, Department of Surgery and Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan  
E-mail: sekky@med.u-toyama.ac.jp

*Abbreviations:* AQP, aquaporin; TMA, tissue microarray; RR, risk ratio; GEM, gemcitabine; UICC, Union for International Cancer Control; FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9

*Key words:* aquaporin, biliary tract carcinoma, tissue microarray, immunohistochemistry

## Introduction

Aquaporins (AQPs) are integral membrane proteins which facilitate the movement of water, and they are expressed in many kinds of cells, especially in polarized epithelial cells (1-3). AQPs are essential for bile water secretion and reabsorption. However, little is known about the function of AQPs water channels in human biliary tract carcinoma. At least 3 AQPs, AQP-1, -4 and -8, are known to be expressed in the biliary tract (4). AQP-1 and -4 are also implicated in the intrahepatic bile duct absorption of water (5). The epithelial cells of human and mouse gallbladder express AQP-1 and -8 (6,7). In the human gallbladder, AQP-1 is localized on both the apical and basolateral plasma membranes of epithelial cells lining the neck portion of the organ (6).

Recently, it seems that AQP has an important role in human carcinogenesis. We previously reported that AQP-5 may be involved in differentiation of human gastric carcinoma cells, and overexpression of several aquaporins has been reported in different types of human carcinoma (8-16). However, the role of AQPs in biliary tract carcinogenesis has not yet been clearly defined. Biliary tract carcinoma, consisting of gallbladder carcinoma and bile duct carcinoma, is a more lethal disease compared to other gastrointestinal cancers. The resection rate and the curative resection rate were 67.0-69.8% and 30.4-37.7%, respectively (17). The five-year survival rate after surgical resection was 41.6% for gallbladder carcinoma, and 33.1% for bile duct carcinoma (17). Surgical resection is the only chance for a cure, however, it is only applicable for selected patients. Thus, in order to understand the mechanisms in biliary tract carcinoma, we evaluated the role of AQPs on biliary tract carcinoma.

## Materials and methods

*Tissue samples.* A series of surgical specimens from patients with biliary tract carcinoma were used. The patients with distant metastasis were excluded from the analysis. We used paraffin-embedded tissues of 81 samples (45 gallbladder carcinoma, 36 bile duct carcinoma) of the patients who underwent surgery from 1997 to 2010 at Toyama University Hospital, Japan. All samples were histologically diagnosed at the Department of Pathology. The final stage of biliary

tract carcinoma was confirmed pathologically according to the TNM classification system of malignant tumors by the UICC, sixth edition.

**Tissue microarray (TMA).** TMAs are composed of small 1.0 mm cores of tissue from patient's paraffin blocks. The formalin-fixed paraffin-embedded (FFPE) blocks used throughout this study contained tumor tissue. For tissue stamping, the tumor areas were marked on H&E-stained sections and marked directly on the corresponding FFPE blocks. Tissue cores were only obtained from tumor-bearing areas. Paraffin-embedded tumor material was cut into 4  $\mu$ m-thick sections and placed onto glass slides. Slides were stained with H&E and examined for histopathology and tissue retention. The remaining sections were stored at room temperature until use (18).

**Immunohistochemical staining.** AQP-1, -4, -5 and -8 expression were analyzed by TMAs (Fig. 1A). The protein expressions of the AQPs were evaluated by the combination of the immunohistological intensity and distribution (18). The plot underwent a primary analysis and a secondary analysis. The average score were used for further study. The final decision was made by discussion of two researchers (S.S. and R.H.). Images of immunohistochemistry staining were photographed under a microscope, and digitized slide images were analyzed (Fig. 1A). Selected micrographs from the TMAs immunostained with polyclonal antibodies raised against AQP-1, -4, -5 and -8 are shown in Fig. 1B. The following primary antibodies were used: anti-AQP-1 (H-55; Santa Cruz Biotechnology, Inc.) antibodies were used at 1:100 dilution. Anti-AQP-4 (H-80) and anti-AQP-8 (H-85) antibodies (Santa Cruz Biotechnology, Inc.) were used at 1:200 dilution. Anti-AQP-5 (H-200; Santa Cruz Biotechnology, Inc.) antibodies were used at 1:50 dilution. The secondary antibodies used were goat anti-rabbit IgG-HRP according to the manufacturer's instructions. The staining intensity was scored as: 0, no staining of carcinoma cells; 1, weak staining; 2, moderate staining; 3, marked staining. The staining distribution within the tumor cells was graded as: 0, <10%; 1,  $\geq$ 10% - <50%; and 2,  $\geq$ 50%. Expression of AQPs in the carcinoma tissue was defined as positive when the sum total of the staining intensity and distribution was 3 or more (Fig. 1C). Polarization pattern were classified into two groups with polarized/mixed pattern or lost polarization pattern (Fig. 1D).

**Postoperative chemotherapy.** There were 17 patients who underwent postoperative chemotherapy after aggressive surgical resection. There were 11 cases of R0 (microscopically margin-negative resection specimen with no residual microscopic or macroscopic tumor in the resection bed) and 6 cases of R1 (macroscopic tumor clearance but microscopically, margins were positive for tumor). As first-line chemotherapy, 7 patients received fluoropyrimidine (S-1) or fluorouracil chemotherapy, and 10 cases received gemcitabine (GEM) plus fluoropyrimidine (S-1) chemotherapy (GS). We analyzed the relationship between AQP expression and prognosis of the 10 patients who received GS treatment (19-21).

**Statistical analysis.** The statistical evaluation was done by Chi-square test and t-test. Prognostic factors were examined

Table I. Patient characteristics.

Terms	N	(%)
Age (years)		
<70 years	36	44.4
$\geq$ 70 years	45	55.6
Gender		
Female	46	56.8
Male	35	43.2
Organ		
Gallbladder	45	55.6
Bile duct	36	44.4
Tumor size (cm)		
<2	16	19.8
$\geq$ 2	65	80.2
Depth of tumor invasion		
T1-T2	43	53.8
T3-T4	38	46.9
Lymph node metastasis		
Negative	49	60.5
Positive	32	39.5
Histological type		
Pap/well/moderate	64	79.0
Poor/others	17	21.0
Lymphovascular invasion		
Negative	36	46.2
Positive	42	53.8
Vascular invasion		
Negative	38	48.7
Positive	40	51.3
Serum tumor markers		
CEA (ng/ml)		
$\leq$ 5	20	23.5
>5	59	74.7
CA19-9 (U/ml)		
$\leq$ 37	46	58.2
>37	33	41.8
Postoperative chemotherapy		
Yes	33	40.7
No	48	59.3

by both univariate and multivariate analyses. Survival curves were estimated using the Kaplan-Meier method, and differences between survival curves were analyzed using the log-rank test. Multivariate analyses were produced using the Cox's proportional hazards model to test the risk of cancer death. The Chi-square model was used for analysis of the factors relating to AQP. All statistical analyses were considered significant




Figure 1. (A) Immunohistochemistry of AQP-5 by tissue microarray (TMA). The plot was analyzed in duplicate. (B) Images of immunohistochemistry staining AQP-1, -4, -5 and -8 in gallbladder carcinoma. (C) AQP-5 expression in bile duct carcinoma. Staining intensity and distribution ranging from 0 to 2 is low expression (left). Scale of 3 to 5 is high expression (right). (D) Expression of AQP-5 in gallbladder carcinoma. (Da) Apical expression, and (Db) loss of polarization pattern.

Table II. The expression of AQP-1, -4, -5 and -8 in the biliary tract carcinoma.

	AQP-1(+)	AQP-4(+)	AQP-5(+)	AQP-8(+)
Gallbladder	23/44	9/45	25/43	12/43
(%)	(52.3)	(20.0)	(58.1)	(27.9)
Bile duct	14/36	4/36	25/36	2/36
(%)	(45.7)	(11.1)	(69.4)	(5.6)
Total	37/80	13/81	49/79	14/79
(%)	(46.3)	(16.0)	(63.2)	(17.2)

at a P-value of 0.05. Statistical analyses were performed by Windows (SAS Institute Inc., NC).

**Results**

*The expression of AQP-1, -4, -5 and -8 protein in biliary tract carcinoma tissues.* The clinicopathological backgrounds of the patients are shown in Table I. Table II shows the AQP expression positivity in the bile duct and gallbladder carcinoma tissue. AQP-4 and -8 were more highly expressed in gallbladder carcinoma than in bile duct carcinoma. AQP-1 and -5 expression ratio was similar in the case of the two organs. Of the two, AQP-5 had the higher positivity. In the 49 high AQP-5 expression cases, loss of the subcellular polarization pattern was detected in 29 cases (Fig. 1D). The rate of AQP-1 was

22/36, AQP-4 was 7/13, and all the 14 high AQP-8 expression were loss of polarization pattern.

*Prognostic impact of AQP expression.* Depth of tumor invasion, lymph node metastasis, TMN stage, tumor size ( $\geq 2.0$ ), histological type, vascular invasion, carcinoembryonic antigen (CEA) ( $\geq 5$ ), and CA19-9 ( $\geq 37$ ) were associated with survival ( $P < 0.001$ , 0.006,  $< 0.001$ , 0.035, 0.002, 0.001,  $< 0.001$  and 0.019, respectively) (Table III). Survival of the patients with high AQP-5 expression was significantly longer than that of the patients in the low AQP-5 expression group ( $P = 0.017$ ). Other AQPs, AQP-1, -4 and -8 had no significant impact on survival (Fig. 2). Furthermore, Cox's proportional hazard model revealed that AQP-5 expression was an independent prognostic factor (RR, 0.34;  $P = 0.012$ ). Depth of tumor invasion




Figure 2. Survival rates of biliary tract carcinoma patients. (A) AQP-1. (B) AQP-5. Kaplan-Meier analysis reveals a significantly less favorable overall survival rate in patients with AQP-5 high expression compared with low AQP-5 expression (log-rank test,  $P=0.017$ ).

Table III. Relationship between patient characteristics and prognosis in biliary tract carcinoma. Univariate and multivariate analyses.

Terms	Univariate analysis		Multivariate analysis	
	P-value	Risk ratio	95% CI	P-value
Age ( $\geq 70$ years)	0.648	1.317	(0.579-3.053)	0.512
Gender (male)	0.818	1.665	(0.660-4.210)	0.278
Depth of tumor invasion (T1/T2)	$<0.001^a$	0.296	(0.089-0.906)	0.033 <sup>b</sup>
Lymph node metastasis (present)	0.006 <sup>a</sup>	1.171	(0.406-3.305)	0.767
Tumor size ( $\geq 2$ )	0.035 <sup>b</sup>	0.948	(0.251-4.776)	0.942
Histological type (pap/well/moderate)	0.002 <sup>a</sup>	0.394	(0.151-1.064)	0.066
Lymphovascular invasion (present)	0.512			
Vascular invasion (present)	0.001 <sup>a</sup>	2.096	(0.788-5.910)	0.139
CEA $>5$ (ng/ml)	$<0.001^a$	7.172	(2.896-18.181)	$<0.001^a$
CA19-9 $>37$ (U/ml)	0.019 <sup>b</sup>	0.865	(0.339-2.183)	0.759
Postoperative chemotherapy (yes)	0.639			
AQP-1 expression (positive)	0.083			
AQP-4 expression (positive)	0.171			
AQP-5 expression (positive)	0.022 <sup>b</sup>	0.382	(0.161-0.884)	0.025 <sup>b</sup>
AQP-8 expression (positive)	0.359			

Cox's proportional hazard model revealed that AQP-5 expression was an independent prognostic factor (RR, 0.382;  $P=0.025$ ). Depth of tumor invasion and CEA  $>5$  U/ml were associated with survival in multivariate analysis. <sup>a</sup> $P<0.01$ ; <sup>b</sup> $P<0.05$ .

(RR, 0.26;  $P=0.011$ ) and CEA (RR, 7.62;  $P<0.001$ ) were also associated with survival in multivariate analysis (Table III).

*Analysis between AQP-1 and -5 expression and various prognostic factors.* We found that depth of tumor invasion and histological type were associated with AQP-1 expression ( $P=0.021$  and  $0.014$ ). AQP-5 expression was significantly associated with tumor size ( $P=0.006$ ) by Chi-square analysis. No other relationship was observed between the clinicopathological characteristics of the patients and AQP-5 expression (Table IV). There was no relationship between high AQP-1 expression and high AQP-5 expression ( $P=0.178$ ) (data not shown). Multivariate logistic models revealed that there were no significant predictors for AQP-1 and -5 expression.

*Relationship between the AQP-5 expression and the response to postoperative chemotherapy.* As first-line chemotherapy,

7 patients received fluoropyrimidine (S-1) or fluorouracil chemotherapy, and 10 cases received gemcitabine (GEM) plus fluoropyrimidine (S-1) chemotherapy (GS). Table V shows prognosis of biliary tract carcinoma patients who received GEM plus S-1 postoperative chemotherapy. Patients with high AQP-5 expression had significantly more favorable rate of both (Fig. 3A) overall and (Fig. 3B) disease-free survival compared to patients with low AQP-5 expression (Fig. 3) (log-rank test;  $P=0.033$  and  $0.002$ ).

## Discussion

The results of the study show that AQP-5 had the most important role in prognosis of biliary tract carcinoma among AQP-1, -4, -5 and -8. The multivariate proportional hazards model revealed that high AQP-5 expression was an independent and favorable prognostic factor. The results of this study differ from previous

Table IV. Relationship between patient characteristics and AQP-1 and AQP-5 in biliary tract carcinoma.

Terms	AQP-1 expression			AQP-5 expression		
	Positive (n=37)	Negative (n=43)	P-value	Positive (n=50)	Negative (n=29)	P-value
Age (years)						
<70	13	23	0.099	25	10	0.178
≥70	24	20		25	19	
Gender						
Female	25	21	0.090	28	17	0.821
Male	12	22		22	12	
Depth of tumor invasion						
T1-T2	24	18	<b>0.039<sup>a</sup></b>	27	14	0.624
T3-T4	13	25		23	15	
Lymph node metastasis						
Absent	23	25	0.714	31	16	0.552
Present	14	18		19	13	
TNM stage						
I/II	27	24	0.109	35	15	0.106
III	10	19		15	14	
Tumor size						
<2	9	6	0.256	13	1	<b>0.006<sup>b</sup></b>
≥2	28	36		37	27	
Histological type						
Pap/well/moderate	34	30	<b>0.011<sup>a</sup></b>	43	20	0.272
Poor/others	3	13		7	9	
Lymphovascular invasion						
Absent	13	23	0.122	22	14	0.074
Present	22	19		27	14	
Vascular invasion						
Absent	20	18	0.307	25	12	0.437
Present	16	23		23	16	
CEA (ng/ml)						
<5	28	30	0.800	39	18	0.145
≥5	9	11		10	10	
CA19-9 (U/ml)						
<37	26	19	<b>0.032<sup>a</sup></b>	31	13	0.152
≥37	11	22		18	15	
Postoperative chemotherapy						
Yes	15	17	0.927	18	14	0.285
No	22	26		32	15	

<sup>a</sup>P<0.05; <sup>b</sup>P<0.01.

studies in colorectal and non-small cell lung cancers (12,22). AQP-5 induced cell proliferation via Ras/ERK/Rb pathway in colorectal cancer (22,23), and it promoted tumor invasion in non-small cell lung cancer (12). Overexpression of AQP-5 increased proliferation and migration in colorectal and non-small cell lung carcinoma. The results of this study suggested that AQP-5 may

play a different role in biliary tract carcinoma, such as facilitation of bile transport and reabsorption. The roles of biliary epithelium were different from those of the colon and of the lung (24).

With regard to the AQP-5 protein distribution (25-29), the expression of AQP-5 in human ovarian tissues was reported to be mainly localized in the basolateral membrane of benign

Table V. Postoperative chemotherapy patients (GEM plus S-1).

No.	Organ	Gender	Age (years)	UICC stage	AQP-5 expression	Survival time (months)	Prognosis	Recurrence (months)	Cause of death	Postoperative chemotherapy
1	BD	F	72	2a	Positive	26.5	DF	(-)		GEM+S-1
2	BD	F	62	3	Positive	26.9	DF	(-)		GEM+S-1
3	BD	F	64	3	Positive	16.0	DF	(-)		GEM+S-1
4	BD	M	58	1b	Positive	51.7	DF	(-)		GEM+S-1
5	BD	M	79	1b	Positive	32.9	DF	(-)		GEM+S-1
6	GB	F	63	3	Negative	12.8	Dead	5.4	Liver metastasis	GEM+S-1
7	BD	F	63	3	Negative	8.7	Reccurence (liver)	3.9		GEM+S-1
8	BD	F	80	2b	Negative	26.7	Reccurence (liver)	20.7		GEM+S-1
9	BD	M	51	3	Negative	16.2	Dead	6.2	Bone metastasis	GEM+S-1
10	BD	M	69	1b	Negative	7.2	Dead	2.2	Peritoneal dissemination	GEM+S-1




Figure 3. Survival rates of biliary tract carcinoma patients who received GEM plus S-1 postoperative chemotherapy. Kaplan-Meier analysis reveals a significantly less favorable (A) overall and (B) disease-free survival rate in patients without AQP-5 expression compared with those with AQP-5 expression (log-rank test,  $P=0.033$ ,  $0.002$ ). \* $P<0.05$ ; \*\* $P<0.01$ .

tumor cells and apical and basolateral membranes of borderline cells, or scattered in the membrane of malignant cells, and absent in the normal epithelium (30). The results of our study were consistent with this report and AQP-5 expression was mixed or lost polarization and scattered in the membrane in more than half of the patients. AQP-1, -4 and -8 also show similar features. The expression of AQP-5 was associated with small tumor size in biliary tract cancer. This phenomenon was also observed in colon carcinoma (9,16). However, AQP expression was maintained through the late stage of colon carcinoma. These results suggested that AQP-5 was included in early-stage disease and might represent a functional ability of bile transfer channel in biliary tract carcinoma.

Not only AQP-5 but also AQP-1 expression were correlated with clinicopathological factors. Similar AQP-1 and -5 expression patterns were observed in pancreatic carcinoma (31). Furthermore, negative AQP-1 expression was an independent prognostic factor in intrahepatic cholangiocarcinoma (32). Thus, AQP-1 also have some role in hepatobiliary and pancreatic carcinoma.

With regard to chemotherapy for biliary tract carcinoma, gemcitabine (GEM) and S-1 are commonly used. Although

our study size was small, high AQP-5 expression showed an inverse association ( $P=0.011$ ) with postoperative recurrence. The data suggested that expression of AQP-5 may play an important role in drug sensitivity. AQPs may be attractive targets for the development of novel drug therapies for disorders that involve aberrant water movement (33-36). However discovery of additional roles of AQPs is necessary.

In conclusion, this study shows that AQP-5 is highly expressed in biliary tract carcinoma. High AQP-5 expression was associated with small tumor size and favorable prognosis of biliary tract carcinoma patients. Our result suggest that AQPs expression demonstrates prognosis and drug sensitivity in biliary tract carcinoma. Further study of AQPs would contribute to the clinically treatment for biliary tract cancer.

#### Acknowledgements

We thank Mr. Mikuni Nemoto for technical support. This study was supported by KAKENHI Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

**References**

1. Verkman AS and Mitra AK: Structure and function of aquaporin water channels. *Am J Physiol Renal Physiol* 278: F13-F28, 2000.
2. Brown D, Katsura T, Kawashima M, *et al*: Cellular distribution of the aquaporins: a family of water channel proteins. *Histochem Cell Biol* 104: 1-9, 1995.
3. Mobasheri A and Marples D: Expression of the AQP-1 water channel in normal human tissues: a semiquantitative study using tissue microarray technology. *Am J Physiol Cell Physiol* 286: C529-C537, 2004.
4. Portincasa P, Palasciano G, Svelto M, *et al*: Aquaporins in the hepatobiliary tract. Which, where and what they do in health and disease. *Eur J Clin Invest* 38: 1-10, 2008.
5. Masyuk AI, Gong AY, Kip S, *et al*: Perfused rat intrahepatic bile ducts secrete and absorb water, solute, and ions. *Gastroenterology* 119: 1672-1680, 2000.
6. Nielsen S, Smith BL, Christensen EI, *et al*: Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. *Proc Natl Acad Sci USA* 90: 7275-7279, 1993.
7. Calamita G, Ferri D, Bazzini C, *et al*: Expression and subcellular localization of the AQP8 and AQP1 water channels in the mouse gall-bladder epithelium. *Biol Cell* 97: 415-423, 2005.
8. Watanabe T, Fujii T, Oya T, *et al*: Involvement of aquaporin-5 in differentiation of human gastric cancer cells. *J Physiol Sci* 59: 113-122, 2009.
9. Woo J, Lee J, Chae YK, *et al*: Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. *Cancer Lett* 264: 54-62, 2008.
10. Zhang ZQ, Zhu ZX, Bai CX, *et al*: Aquaporin 5 expression increases mucin production in lung adenocarcinoma. *Oncol Rep* 25: 1645-1650, 2011.
11. Mazal PR, Susani M, Wrba F, *et al*: Diagnostic significance of aquaporin-1 in liver tumors. *Hum Pathol* 36: 1226-1231, 2005.
12. Chae YK, Woo J, Kim MJ, *et al*: Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. *PLoS One* 3: e2162, 2008.
13. Zhang Z, Chen Z, Song Y, *et al*: Expression of aquaporin 5 increases proliferation and metastasis potential of lung cancer. *J Pathol* 221: 210-220, 2010.
14. Shen L, Zhu Z, Huang Y, *et al*: Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. *Biomed Pharmacother* 64: 313-318, 2010.
15. Mobasheri A, Airley R, Hewitt SM, *et al*: Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: a study using high density multiple human tumor tissue microarrays. *Int J Oncol* 26: 1149-1158, 2005.
16. Moon C, Soria JC, Jang SJ, *et al*: Involvement of aquaporins in colorectal carcinogenesis. *Oncogene* 22: 6699-6703, 2003.
17. Miyakawa S, Ishihara S, Horiguchi A, *et al*: Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. *J Hepatobiliary Pancreat Surg* 16: 1-7, 2009.
18. Fukuoka J, Fujii T, Shih JH, *et al*: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. *Clin Cancer Res* 10: 4314-4324, 2004.
19. Murakami Y, Uemura K, Sudo T, *et al*: Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. *Ann Surg* 250: 950-956, 2009.
20. Skipworth JR, Olde Damink SW, Imber C, *et al*: Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. *Aliment Pharmacol Ther* 34: 1063-1078, 2011.
21. Park HS, Lim JY, Yoon DS, *et al*: Outcome of adjuvant therapy for gallbladder cancer. *Oncology* 79: 168-173, 2010.
22. Kang SK, Chae YK, Woo J, *et al*: Role of human aquaporin 5 in colorectal carcinogenesis. *Am J Pathol* 173: 518-525, 2008.
23. Woo J, Lee J, Kim MS, *et al*: The effect of aquaporin 5 overexpression on the Ras signaling pathway. *Biochem Biophys Res Commun* 367: 291-298, 2008.
24. Machida Y, Ueda Y, Shimasaki M, *et al*: Relationship of aquaporin 1, 3, and 5 expression in lung cancer cells to cellular differentiation, invasive growth, and metastasis potential. *Hum Pathol* 42: 669-678, 2011.
25. Ma T, Song Y, Gillespie A, *et al*: Defective secretion of saliva in transgenic mice lacking aquaporin-5 water channels. *J Biol Chem* 274: 20071-20074, 1999.
26. Krane CM, Melvin JE, Nguyen HV, *et al*: Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation. *J Biol Chem* 276: 23413-23420, 2001.
27. Song Y and Verkman AS: Aquaporin-5 dependent fluid secretion in airway submucosal glands. *J Biol Chem* 276: 41288-41292, 2001.
28. Matsuzaki T, Tajika Y, Suzuki T, *et al*: Immunolocalization of the water channel, aquaporin-5 (AQP5), in the rat digestive system. *Arch Histol Cytol* 66: 307-315, 2003.
29. Matsuzaki T, Tajika Y, Ablimit A, *et al*: Aquaporins in the digestive system. *Med Electron Microsc* 37: 71-80, 2004.
30. Yang JH, Shi YF, Cheng Q, *et al*: Expression and localization of aquaporin-5 in the epithelial ovarian tumors. *Gynecol Oncol* 100: 294-299, 2006.
31. Burghardt B, Elkaer ML, Kwon TH, *et al*: Distribution of aquaporin water channels AQP1 and AQP5 in the ductal system of the human pancreas. *Gut* 52: 1008-1016, 2003.
32. Aishima S, Kuroda Y, Nishihara Y, *et al*: Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. *Hum Pathol* 38: 1819-1825, 2007.
33. Wang F, Feng XC, Li YM, *et al*: Aquaporins as potential drug targets. *Acta Pharmacol Sin* 27: 395-401, 2006.
34. Jeyaseelan K, Sepramaniam S, Armugam A, *et al*: Aquaporins: a promising target for drug development. *Expert Opin Ther Targets* 10: 889-909, 2006.
35. Saadoun S, Papadopoulos MC, Hara-Chikuma M, *et al*: Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. *Nature* 434: 786-792, 2005.
36. Verkman AS: More than just water channels: unexpected cellular roles of aquaporins. *J Cell Sci* 118: 3225-3232, 2005.